JAK1 and rheumatoid arthritis: New highly effective treatments for RA are orally-available Janus Kinase (JAK) inhibitors, such as tofacitinib (JAK1/JAK3 inhibitor) and baricitinib (JAK1/JAK2 inhibitor) that target the JAK/STAT pathway.